Indication: For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Pharmacology: Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that Carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Mechanism Of Action: Carmustine causes cross-links in DNA and RNA, leading to the inhibition of DNA synthesis, RNA production and RNA translation (protein synthesis). Carmustine also binds to and modifies (carbamoylates) glutathione reductase. This leads to cell death.
Drug Category: Antineoplastic Agents; ATC:L01AD01
Brand Names/Synonyms: BCNU; Becenun; Bi Cnu; Bicnu; Bischlorethylnitrosourea; Bischlorethylnitrosurea; Carmubris; Carmustin; Carmustine; FDA 0345; Gliadel; Gliadel Wafer; Nitrumon; SRI 1720
Dosage Forms: 100 mg single dose vials of lyophilized material
Absorption: 5 to 28% bioavailability
Interactions:
DrugBank: Interactions for Carmustine
Interactions for Carmustine:
No information provided.
Chemical IUPAC Name: N-(2-chloroethyl)-1-(2-chloroethylamino)-N-nitroso-methanamide
Chemical Formula: C5H9Cl2N3O2
Half Life: 15-30 minutes
Drug Type: Approved Drug
# Accession No: APRD00006
CAS Registry Number: 154-93-8
Carmustine News (When available)
Supplementary protection certificates: the concept of the ...Dec 29, 2005 Droit et Nouvelles Technologies, Gliadel, being used to treat recurrent brain tumours in addition to surgery, is composed of an active substance, carmustine, and a polymeric, biodegradable ...
NeoPharm, Inc. Announces PRECISE Trial UpdateDec 27, 2005 Genetic Engineering News, A GLIADEL(R) Wafer delivers BCNU (known as carmustine), a commonly used chemotherapeutic anti-tumor agent for GBM, directly to the brain tumor resection cavity ...
NeoPharm, Inc. Announces PRECISE Trial UpdateDec 27, 2005 Finanzen.net, A GLIADEL(R) Wafer delivers BCNU (known as carmustine), a commonlyused chemotherapeutic anti-tumor agent for GBM, directly to the braintumor resection cavity. ...
MGI PHARMA to Present at the JPMorgan Healthcare ConferenceDec 21, 2005 Genetic Engineering News, MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ...
Breakthrough Cancer Treatment Approved in Scotland but Still not ...Dec 12, 2005 PR Newswire UK (press release), Gliadel Implant is an innovative chemotherapy (carmustine) treatment in the form of small 5 pence-sized biodegradable discs that are inserted into the tumour ...
MGI Pharma Still A 'Solid Company' Despite Mixed GuidanceJan 11, 2006 Forbes ...$30 after the company pre-announced slightly lower-than-expected fourth-quarter sales of Aloxi, its post-chemotherapy nausea treatment, and Gliadel, a brain ...
UPDATE 1-MGI Pharma 2006 revenue outlook below expectationsJan 10, 2006 Reuters The company said it expects to recognize about $8.5 million in fourth-quarter 2005 sales of Gliadel Wafer, a brain cancer treatment, and $34 million for the ...
MGI Pharma provides '06 sales guidanceJan 10, 2006 Twin Cities Business Journal, Sales of Gliadel Wafer, a brain tumor treatment acquired in MGI Pharma's purchase of Guilford Pharmaceuticals in October, rose 22 percent to $34 million in 2005 ...
NeoPharm, Inc. Announces PRECISE Trial UpdateDec 27, 2005 Genetic Engineering News, ...of 160 deaths to evaluate potential superiority (p less than or equal to 0.005) of long term patient survival of cintredekin besudotox over Gliadel(R) Wafer ...
MGI PHARMA Provides Corporate Update; 2005 Aloxi(R) Injection ...Jan 10, 2006 Genetic Engineering News, Guilford Pharmaceuticals acquisition on October 3, 2005, MGI PHARMA expects to recognize approximately $8.5 million in fourth quarter sales of Gliadel(R) Wafer ...
NeoPharm, Inc. Announces PRECISE Trial UpdateDec 27, 2005 Finanzen.net, ...population, andcompare overall survival, drug safety and quality of life of patientsreceiving cintredekin besudotox with patients receiving GLIADEL(R)Wafer in ...
Neopharm Study Can ContinueDec 27, 2005 TheStreet.com ...significant improvement in long-term patient survival over MGI Pharma's (MOGN:Nasdaq - commentary - research - Cramer's Take) Gliadel chemotherapy wafer. ...
NeoPharm shares jump 53% on panel OKDec 28, 2005 Chicago Sun-Times, The study of 294 patients is designed to see whether NeoPharm's drug is superior to MGI Pharma's Gliadel, an implantable brain-tumor treatment, in improving ...
Neopharm stock jumps on brain cancer studyDec 27, 2005 United Press International ...will compare overall survival, drug safety and quality of life of patients receiving Neopharm's drug with patients receiving MGI Pharma's Gliadel Wafer.
FREE DRUG FOR CANCERDec 12, 2005 Glasgow Daily Record, ...patients in Scotland. The Scottish Medicines Consortium have given the green light for Gliadel to be offered on the NHS. It supplies ...
Supplementary protection certificates: the concept of the ...Dec 29, 2005 Droit et Nouvelles Technologies, Institute of Technology (hereafter: ‘MIT’) is the holder of a European patent filed in 1987 and a German marketing authorization granted for Gliadel in 1999 ...
NeoPharm brain-cancer trial backed; shares soarDec 27, 2005 Reuters ...survival, drug safety and quality of life of patients receiving IL13 with patients receiving MGI Pharma Inc.'s (MOGN.O: Quote, Profile, Research) Gliadel Wafer ...
NeoPharm brain-cancer trial backedDec 27, 2005 San Diego Union Tribune, ...is designed to compare overall survival, drug safety and quality of life of patients receiving IL13 with patients receiving MGI Pharma Inc.'s Gliadel Wafer. ...
Neopharm clears a key hurdleDec 28, 2005 Chicago Tribune, Using the current existing treatment known as Gliadel Wafer, median survival is 28 weeks, which means Neopharm's IL-13 has to improve median survival to 42 ...
MGI PHARMA to Present at the JPMorgan Healthcare ConferenceDec 21, 2005 Genetic Engineering News, MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ...
UPDATE 1-MGI Pharma 2006 revenue outlook below expectationsJan 10, 2006 Reuters The company said it expects to recognize about $8.5 million in fourth-quarter 2005 sales of Gliadel Wafer, a brain cancer treatment, and $34 million for the ...
MGI Pharma provides '06 sales guidanceJan 10, 2006 Twin Cities Business Journal, Sales of Gliadel Wafer, a brain tumor treatment acquired in MGI Pharma's purchase of Guilford Pharmaceuticals in October, rose 22 percent to $34 million in 2005 ...
Neopharm stock jumps on brain cancer studyDec 27, 2005 United Press International ...will compare overall survival, drug safety and quality of life of patients receiving Neopharm's drug with patients receiving MGI Pharma's Gliadel Wafer.
Neopharm Study Can ContinueDec 27, 2005 TheStreet.com ...after notification of 215 deaths, to demonstrate superiority (p less than or equal to 0.048) of long-term survival of cintredekin besudotox over Gliadel wafer. ...
NeoPharm brain-cancer trial backed; shares soarDec 27, 2005 Reuters ...survival, drug safety and quality of life of patients receiving IL13 with patients receiving MGI Pharma Inc.'s (MOGN.O: Quote, Profile, Research) Gliadel Wafer ...
NeoPharm brain-cancer trial backedDec 27, 2005 San Diego Union Tribune, ...is designed to compare overall survival, drug safety and quality of life of patients receiving IL13 with patients receiving MGI Pharma Inc.'s Gliadel Wafer. ...
Neopharm clears a key hurdleDec 28, 2005 Chicago Tribune, Using the current existing treatment known as Gliadel Wafer, median survival is 28 weeks, which means Neopharm's IL-13 has to improve median survival to 42 ...
